Dongfang Baitai

Beijing Dongfang Baitai Biotech is a clinical-stage Chinese biopharmaceutical company focused on the development and commercialization of innovative antibody therapeutics and high-quality biosimilars. Founded in 2005 and headquartered in Beijing, the company has established a comprehensive platform for antibody discovery, optimization, and large-scale GMP manufacturing. Its pipeline includes a diverse range of monoclonal and bispecific antibodies targeting oncology, cardiovascular diseases, and autoimmune disorders. Notable programs include candidates targeting PCSK9 for hyperlipidemia and various biosimilars for established blockbusters like bevacizumab and cetuximab. The company operates significant manufacturing facilities in the Beijing Economic-Technological Development Area to support its clinical and future commercial needs.